Go Back

Infography: planning an oncology study with eCOA/ePRO

21 February 2017

The FDA has provided guidance on methodology to be used for developing and using PRO in oncology drug development programmes, and has emphasized the increased importance on patient input in clinical trials. In addition to QoL, many PRO questionnaires are used to assess complementary areas in oncology study, including: disease related symptoms (pain or fatigue), physical/social/emotional aspects, symptomatic adverse events, and satisfaction with the care provided.

Using eCOA for oncology trials can be particularly challenging because of the range of therapeutic approaches. Key components should be taken into consideration in your oncology study to ensure the success of eCOA implementation.

To download the infography, click here:

Capture d’écran 2017-02-21 à 14.31.14



  • 30 October
    OCT Nordics - October 30th & 31st - Copenhagen, Denmark - Booth #10 - Schedule a meeting with Kayentis OCT Nordics 2018
  • 06 November
    OCT New England - November 6th & 7th - Boston, MA - Booth #46 - Schedule a meeting with Kayentis OCT New England
  • 11 November
    DIA Japan - November 11th - November 13th - Tokyo, Japan Schedule a meeting with Kayentis
  • 13 November
    DMB Paris - November 13th - Paris, France Schedule a meeting with Kayentis  
  • Follow us

    Download our brochure